AstraZeneca’s LATIFY phase III trial of ceralasertib plus Imfinzi in previously treated advanced NSCLC fails to meet primary endpoint: Cambridge, UK Tuesday, December 23, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback